EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ablation of pulmonary oligometastasis in advanced hepatocellular carcinoma treated with Lenvatinib: a retrospective multicenter study

Ye Li, Yigong Ren, Hui Li, Ruixia Li, Hongji You, Yanyang Zhang, Wei Wang, Mingyu Liu, Zhimei Huang, Qunfang Zhou iD, Feng Duan

Therapeutic Advances in Medical Oncology · 2026-03 · 18

DOI: 10.1177/17588359261432042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 19.03.2026. Verfasst von Ye Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Science Fund for Distinguished Young Scholars of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with hepatocellular carcinoma (HCC) and pulmonary oligometastasis (PO), the therapeutic effects of metastases ablation remain unclear.

Objective

This study aimed to compare the efficacy of metastases ablation combined with Lenvatinib (Ablation + Len) with that of Lenvatinib alone (Len) in patients with HCC and PO.

Design

A multicenter retrospective study.

Methods

This study included 202 patients in the Len group and 182 patients in the Ablation + Len group. Propensity score matching and inverse probability treatment weighting analyses were used to balance baseline variables between the two groups. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was overall survival (OS).

Results

The median PFS time was 11.0 ± 0.3 and 14.1 ± 0.5 months in the Len and Ablation + Len groups, respectively. The PFS (hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.49–0.80, p < 0.001) and OS (HR, 0.60; 95% CI, 0.42–0.86; p = 0.006) times were significantly longer in the Ablation + Len group than in the Len group. The OS (HR, 0.62; 95% CI, 0.37–1.03; p = 0.071) and PFS (HR, 0.77; 95% CI, 0.51–1.17; p = 0.230) did not differ among patients with hepatic tumors in stable disease (SD) status. However, among patients in partial response, the OS (HR, 0.57; 95% CI, 0.34–0.95; p = 0.030) and PFS (HR, 0.50; 95% CI, 0.37–0.69; p < 0.001) were significantly different between the two groups.

Conclusion

Ablation of PO combined with Lenvatinib resulted in longer PFS and OS than treatment with Lenvatinib alone. However, patients did not derive survival benefits from the ablation of metastases when the hepatic tumors were in SD status.

Schlagwörter

Stichwörter der Autor:innen

ablationadvanced hepatocellular carcinomalenvatinibprognosispulmonary oligometastasis

Autor:innen und Institutionen

  • Department of Interventional Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Department of Liver Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Department of Nuclear Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
  • Department of Interventional Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China.
  • Department of General surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, China.

ORCID-Profile: Qunfang Zhou

Förderung

  • National Natural Science Foundation of China
  • Science Fund for Distinguished Young Scholars of Guangdong Province

Zitieren

APA

Li, Y., Ren, Y., Li, H., Li, R., You, H., Zhang, Y., Wang, W., Liu, M., Huang, Z., Zhou, Q., & Duan, F. (2026). Ablation of pulmonary oligometastasis in advanced hepatocellular carcinoma treated with Lenvatinib: a retrospective multicenter study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261432042

Vancouver

Li Y, Ren Y, Li H, Li R, You H, Zhang Y, et al. Ablation of pulmonary oligometastasis in advanced hepatocellular carcinoma treated with Lenvatinib: a retrospective multicenter study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261432042

BibTeX
@article{Li2026,
  author = {Li, Ye and Ren, Yigong and Li, Hui and Li, Ruixia and You, Hongji and Zhang, Yanyang and Wang, Wei and Liu, Mingyu and Huang, Zhimei and Zhou, Qunfang and Duan, Feng},
  title = {Ablation of pulmonary oligometastasis in advanced hepatocellular carcinoma treated with Lenvatinib: a retrospective multicenter study},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261432042}
}
Kostenlos starten →